Physician profile
Paul Phail
NPI 1336554674
$2,314.60
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,296 · 2020: $255 · 2021: $107 · 2022: $635 · 2024: $21.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $21.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $311.92 | 2019-2022 | |
| Amgen INC. | $248.32 | 2019-2022 | |
| Novo Nordisk INC | $206.58 | 2019-2024 | Wegovy |
| Lilly USA, LLC | $192.77 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.84 | 2019-2022 | |
| Abbvie INC. | $158.49 | 2021-2022 | |
| Pfizer INC. | $115.31 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $111.63 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.97 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $73.59 | 2019-2022 | |
| Allergan, INC. | $70.42 | 2019-2020 | |
| Glaxosmithkline, LLC. | $66.54 | 2019-2022 | |
| Genentech USA, INC. | $57.25 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $54.21 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $47.83 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $46.97 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.87 | 2019-2022 | |
| Mylan Specialty L.P. | $43.12 | 2019 | |
| Sanofi-Aventis U.S. LLC | $30.36 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $28.35 | 2019 | |
| Astellas Pharma US INC | $24.30 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.73 | 2022 | |
| Abbott Laboratories | $17.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.14 | 2022 | |
| Organon LLC | $14.92 | 2022 | |
| Lucid Diagnostics INC. | $14.55 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.06 | 2020 | |
| Therapeuticsmd, INC. | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Phail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.